Associate Professor Anna Ralph
Head of Global Health Division and senior clinical research fellow
PhD, Australian National University, 2010; Fellow of the Royal Australasian College of Physicians, 2005; Diploma of Hygiene and Tropical Medicine, University of London, 2002; Master of Public Health, University of Sydney, 1999; Bachelor of Medicine and Bachelor of Surgery Honours Class 1, University of New South Wales, 1996; Medical Science Honours Class 1, Australian National University, 1993; Bachelor of Medical Science, University of Tasmania, 1992.
Approved level of HDR supervision at Charles Darwin University:
Supervisor for PhD
Her research fields include rheumatic fever / rheumatic heart disease in Australian Indigenous populations, tuberculosis control especially in neighbouring South-East Asian settings, and improving inter-cultural communication between healthcare providers and clients. She has expertise in a broad range of quantitative and qualitative research methods.
Anna is an executive steering committee member of the Australian Clinical Research Network and the Australasian Society for Infectious Diseases Clinical Research Network.
She supervises a number of PhD students, post doctoral researchers, and Advanced Trainees in Infectious Diseases through the Royal Australasian College of Physicians.
- The Tropical Disease Regional Research Collaborative Initiative (TDRRCI)
- Secondary Prophylaxis Plus (SPPlus: expanding RHD prevention
- HOT NORTH
- The Communicate study
- Strengthening health systems to improve the delivery of tuberculosis contact investigation and preventive therapy in Timika (Indonesia) and Kota Kinabalu (Malaysia)
- Embedding sustained improvements in TB diagnosis and management into practice in eastern Malaysia
- Understanding the molecular epidemiology of TB in Sabah, Malaysia
- Improving the diagnosis of ARF
- Enhanced models of secondary prevention for RHD
- On Track Watch: a grassroots Rheumatic Heart Disease initiative in the Northern Territory
- Determinants and outcomes of adherence to secondary prophylaxis for ARF
- Improving delivery of secondary prophylaxis for rheumatic heart disease: a stepped-wedge, community-randomised trial (2012-2016).
- Ralph AP, de Dassel JL, Kirby A, Read C, Mitchell AG, Maguire GP, Currie BJ, Bailie RS, Johnston V, Carapetis JR. Improving delivery of secondary prophylaxis for rheumatic heart disease in a high-burden setting: outcome of a stepped-wedge, community, randomized trial. J Am Heart Assoc. 2018;7:e009308. DOI: 10.1161/JAHA.118.009308.
- Coffey PM, Ralph AP, Krause VL. The role of social determinants of health in the risk and prevention of group A streptococcal infection, acute rheumatic fever and rheumatic heart disease: A systematic review. PLoS Negl Trop Dis. 2018 Jun 13;12(6):e0006577.
- Myint NPST, Aung NM, Win MS, Htut TY, Ralph AP, Cooper DA, Nyein ML, Kyi MM, Hanson J. The clinical characteristics of adults with rheumatic heart disease in Yangon, Myanmar: An observational study. PLoS One. 2018 Feb 21;13(2):e0192880.
- de Dassel JL, Ralph AP, Cass A. A systematic review of adherence in Indigenous Australians: an opportunity to improve chronic condition management. BMC Health Services Research 2017
- Katzenellenbogen JM, Ralph AP, Wyber R, Carapetis JR. Rheumatic heart disease: infectious disease origin, chronic care approach. BMC Health Serv Res. 2017 Nov 29;17(1):793.
- Mitchell AG, Belton S, Johnston V, Read C, Scrine C, Ralph AP. Aboriginal children and penicillin injections for rheumatic fever: how much of a problem is injection pain? Aust N Z J Public Health. 2017 Nov 22
- Ralph AP, Lowell A, Murphy J, Dias T, Butler D, Spain B, Hughes JT, Campbell L, Bauert B, Salter C, Tune K, Cass A. Low uptake of Aboriginal interpreters in healthcare: exploration of current use in Australia's Northern Territory. BMC Health Serv Res. 2017 Nov 15;17(1):733. doi: 10.1186/s12913-017-2689-y.
- Ralph AP, Rashid Ali MRS, William T, Piera K, Parameswaran U, Bird E, Wilkes CS, Lee WK, Yeo TW, Anstey NM. Vitamin D and activated vitamin D in tuberculosis in equatorial Malaysia: a prospective clinical study. BMC Infect Dis. 2017 Apr 27;17(1):312.
- Ralph AP, Waramori G, Pontororing GJ, Kenangalem E, Wiguna A, Tjitra E, et al. L-arginine and Vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial. PLoS ONE. 2013;8(8):e70032.
- Ralph AP, Lucas RM, Norval M. Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis. Lancet Infect Dis 2013;13:77-88.
Click here to view more Anna Ralph publications in PubMed.
Northern Territory data has been used to prove that timely treatment for people with rheumatic fever reduces the risk of recurring illness and death.
When researchers from Menzies School of Health Research starting working with us on rheumatic heart disease, we explained that the children needed better nutrition.
Media Release | University of Otago
The joint study by researchers from the University of Otago, ESR, University of Auckland and the Menzies School of Health Research, Australia.
The Northern Territory is home to some of the highest known rates of rheumatic heart disease in the world, but the transient nature of the region's medical practitioners could be hindering the fight to stop it.
A poster presentation on a study of patient-provider intercultural communication at Royal Darwin Hospital and consequently Aboriginal patient health outcomes, measured using quantitative and qualitative data.
Australian and Papua New Guinean research groups will work in partnership to address malaria, tuberculosis and other health security threats, under a new grants program funded by the Australian government.
A team of malaria experts from a large international research collaboration has today published results supporting the need for a radical cure strategy to tackle one of the most debilitating forms of malaria caused by the Plasmodium vivax parasite.
Health activities driven by remote Indigenous communities may be key to the sustainable and successful treatment and prevention of a potentially fatal disease, a study has found.
Menzies is collaborating with the Burnet Institute to deliver training in the prevention and eradication of tuberculosis (TB) to 25 visiting Indonesian health professionals.
Associate Professor Anna Ralph awarded an internationally renowned Fulbright Scholarship to help eliminate rheumatic heart disease (RHD) in Australia.
DARWIN’S Menzies School of Health Research will work with the Telethon Kids Institute to develop a cutting edge diagnostic tool to detect acute rheumatic fever.
Read about our HOT NORTH collaboration in the latest Territory Q Magazine.
Tuberculosis - Medical Republic Why haven’t we eliminated TB already?
The Northern Territory has the highest rate of rheumatic heart disease in the world, which is partly due to poor living conditions such as overcrowded housing, said Associate Professor Anna Ralph from the Menzies School of Health Research.
Work will begin to help close critical gaps in healthcare across northern Australia as the result of a $6m grant awarded today to Menzies School of Health Research (Menzies) by the National Health and Medical Research Council (NHMRC).
A $2m research grant to work towards the prevention, control and elimination of malaria and tuberculosis (TB) in Southeast Asia and the Pacific has been awarded to a consortium led by Menzies School of Health Research, in collaboration with Burnet Institute, the Department of Foreign Affairs and Trade announced today.
Australian researchers have uncovered a link between low levels of the gas nitric oxide in the lungs of tuberculosis patients and the body’s ability to fight the deadly disease, opening the door to potential new treatments.
Journal of Infectious Diseases: Impaired Pulmonary Nitric Oxide Bioavailability in Pulmonary Tuberculosis
Impaired Pulmonary Nitric Oxide Bioavailability in Pulmonary Tuberculosis: Association with Disease Severity and Delayed Mycobacterial Clearance with Treatment.
New research from the Menzies School of Health Research could open the door to the development of new treatments for Tuberculosis (TB).
With a history as long as mankind’s, TB lies dormant in one third of our global population.